Author:
Regan James,Flynn James P.,Choudhary Manish C.,Uddin Rockib,Lemieux Jacob,Boucau Julie,Bhattacharyya Roby P.,Barczak Amy K.,Li Jonathan Z.,Siedner Mark J.
Abstract
AbstractThe US Centers for Disease Control and Prevention recommends rapid testing for SARS-CoV-2 infection as a key element of epidemic control. The Abbott BinaxNow is in widespread use in the United States for self-testing and as part of public health screening campaigns, but has not been evaluated for use with the omicron variant of SARS-CoV-2. We recruited individuals testing positive for COVID-19 PCR at an academic medical center. Anterior nasal swabs were stored in viral transport media and evaluated by viral load quantification and whole genome sequencing. We created serial dilutions from 2.5×103-2.5×105 viral copies/specimen for two delta and omicron specimens, respectively, and tested each with the BinaxNow assay per manufacturer instructions. Results were interpreted by three readers, blinded to the specimen variant and concentration. All omicron and delta specimens with concentrations of 100,000 copies/swab or greater were positive by the BinaxNow Assay, a concentration similar to previously reported limits of detection for this assay. Assay sensitivity diminished below that. This study demonstrates that Omicron variant SARS-CoV-2 infections are detected by the BinaxNow rapid antigen assay. Additional laboratory and clinical validation assessments are needed to better determine their limits of detection and performance in real-world settings.
Publisher
Cold Spring Harbor Laboratory
Reference12 articles.
1. Interim Guidance for Antigen Testing for SARS-CoV-2. United States Centers for Disease Control and Prevention. [Internet]. 2020 [cited 2021 Dec 20]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html
2. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020
3. Okoye NC , Barker AP , Curtis K , Orlandi RR , Snavely EA , Wright C , et al. Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting. Journal of Clinical Microbiology [Internet]. 2021 Jan 28[cited 2021 Dec 20]; Available from: https://journals.asm.org/doi/abs/10.1128/JCM.03282-20
4. Almendares O , Prince-Guerra JL , Nolen LD , Gunn JKL , Dale AP , Buono SA , et al. Performance characteristics of the Abbott BinaxNOW SARS-CoV-2 antigen test in comparison to real-time RT-PCR and viral culture in community testing sites during November 2020. Journal of Clinical Microbiology [Internet]. 2021 Oct 27[cited 2021 Dec 20]; Available from: https://journals.asm.org/doi/abs/10.1128/JCM.01742-21
5. Point-of-Care Antigen Test for SARS-CoV-2 in Asymptomatic College Students;Emerg Infect Dis,2021